362 related articles for article (PubMed ID: 34875652)
1. Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.
Chu X; Hong Y; Wang Y; Yu C; Wang L; Tong H; Yan J; Zhang Z; Xu G; Yao Y; Zeng R
Am J Nephrol; 2021; 52(12):899-908. PubMed ID: 34875652
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of protein A immunoadsorption and therapeutic plasma exchange in ANCA-associated vasculitis with severe renal involvement: a retrospective study.
Liu X; Xia M; Liu D; Liu H; Tang C; Chen G; Liu Y; Yuan F; Liu H
Ann Med; 2023 Dec; 55(1):2230875. PubMed ID: 37452682
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of protein A immunoadsorption therapy on severe ANCA-associated vasculitis renal injury.
Song J; Liu H; Chen X; Zhou L; Sun C; Yuan F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1026-1032. PubMed ID: 37724405
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series.
Caroti L; Cirami CL; Di Maria L; Larti A; Carta P; Dervishi E; Farsetti S; Tsalouchos A; Novelli L; Minetti EE
BMC Nephrol; 2019 May; 20(1):162. PubMed ID: 31088509
[TBL] [Abstract][Full Text] [Related]
8. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
9. Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Gopaluni S; Flossmann O; Little MA; O'Hara P; Bekker P; Jayne D;
Arthritis Rheumatol; 2019 May; 71(5):784-791. PubMed ID: 30418705
[TBL] [Abstract][Full Text] [Related]
10. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
11. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.
McAdoo SP; Medjeral-Thomas N; Gopaluni S; Tanna A; Mansfield N; Galliford J; Griffith M; Levy J; Cairns TD; Jayne D; Salama AD; Pusey CD
Nephrol Dial Transplant; 2019 Jan; 34(1):63-73. PubMed ID: 29462348
[TBL] [Abstract][Full Text] [Related]
13. Urinary isomorphic red blood cells for the prediction of disease severity and renal outcomes in MPO-ANCA-associated vasculitis: a retrospective cohort study.
Wang F; Jin Y; Zhou F; Luo L; Tang J; Huang L; Hu X; Liao Z; Jiang Y; Dengshuang L; Ge H; Sun D; Xiao G; Feng J; Li X
J Nephrol; 2023 Nov; 36(8):2295-2304. PubMed ID: 37395920
[TBL] [Abstract][Full Text] [Related]
14. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N; Charles P; Terrier B; Jones RB; Hiemstra T; Mouthon L; Bajema I; Berden A; Thervet E; Guillevin L; Jayne D; Karras A;
Kidney Int; 2023 Jun; 103(6):1144-1155. PubMed ID: 36940799
[TBL] [Abstract][Full Text] [Related]
15. The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis.
Huang L; Zhong Y; Ooi JD; Zhou YO; Zuo X; Luo H; Chen JB; Wu T; Yang Y; Meng T; Xiao Z; Lin W; Ao X; Xiao X; Zhou Q; Xiao P
Int Immunopharmacol; 2019 Nov; 76():105883. PubMed ID: 31536905
[TBL] [Abstract][Full Text] [Related]
16. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center.
Bai YH; Li ZY; Chang DY; Chen M; Kallenberg CG; Zhao MH
Semin Arthritis Rheum; 2018 Feb; 47(4):524-529. PubMed ID: 28917713
[TBL] [Abstract][Full Text] [Related]
17. Urinary Matrix Metalloproteinase 7 Activated by Oxidative Stress Predicts Kidney Prognosis in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu L; Wang G; Yang B; Liu X; Xie C; Feng X; Jin L; Zhou Z; Yang M; Zhou Z; Su C; Li Y; Song Y; Cao W
Antioxid Redox Signal; 2022 Aug; 37(4-6):246-256. PubMed ID: 35152729
[No Abstract] [Full Text] [Related]
18. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
19. Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.
Yoo BW; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Rheumatol; 2020 Mar; 39(3):831-840. PubMed ID: 31802348
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement.
Casal Moura M; Specks U; Tehranian S; Sethi S; Zubidat D; Nardelli L; Dos Santos FG; Sousa C; León-Róman J; Bobart SA; Greene E; Zand L; Fervenza FC
Clin J Am Soc Nephrol; 2023 Jan; 18(1):47-59. PubMed ID: 36526414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
